Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PHVSNYSE:RCUSNASDAQ:RZLTNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHVSPharvaris$17.99+8.1%$16.42$11.51▼$25.50$940.70M-2.8671,606 shs62,025 shsRCUSArcus Biosciences$8.67+1.8%$8.74$6.50▼$18.98$917.54M0.83864,021 shs1.33 million shsRZLTRezolute$4.11+1.0%$3.82$2.22▼$6.19$351.49M1.04582,106 shs2.24 million shsZYMEZymeworks$12.48-1.2%$12.05$8.21▼$17.70$868.32M1.17583,920 shs823,051 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHVSPharvaris0.00%+7.72%+12.51%+16.29%-5.56%RCUSArcus Biosciences0.00%-6.32%-4.20%-5.25%-47.00%RZLTRezolute0.00%-2.14%+5.66%+35.64%+4.05%ZYMEZymeworks0.00%-1.50%+8.15%-4.37%+48.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPHVSPharvaris1.5373 of 5 stars3.51.00.00.01.90.00.0RCUSArcus Biosciences1.5657 of 5 stars4.50.00.00.00.01.70.0RZLTRezolute1.9573 of 5 stars3.61.00.00.00.64.20.0ZYMEZymeworks1.8567 of 5 stars3.50.00.00.02.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHVSPharvaris 3.00Buy$36.20101.22% UpsideRCUSArcus Biosciences 2.90Moderate Buy$24.13178.42% UpsideRZLTRezolute 3.14Buy$11.83187.92% UpsideZYMEZymeworks 2.90Moderate Buy$21.0068.27% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, PHVS, RCUS, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$32.006/5/2025PHVSPharvarisWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ARCUSArcus Biosciences$258M3.56N/AN/A$5.30 per share1.63RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/AZYMEZymeworks$93.38M9.30N/AN/A$6.63 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%N/AZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest RZLT, PHVS, RCUS, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPHVSPharvarisN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHVSPharvarisN/A11.1011.10RCUSArcus Biosciences0.095.375.37RZLTRezoluteN/A8.438.43ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHVSPharvarisN/ARCUSArcus Biosciences92.89%RZLTRezolute82.97%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipPHVSPharvarisN/ARCUSArcus Biosciences9.60%RZLTRezolute18.39%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHVSPharvaris3052.29 millionN/ANot OptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableRZLT, PHVS, RCUS, and ZYME HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 21 at 2:19 AM | marketbeat.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20 at 1:00 PM | zacks.comRhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)June 20 at 3:14 AM | marketbeat.comDuncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)June 19, 2025 | marketbeat.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comSG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)June 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)June 15, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?June 13, 2025 | marketbeat.comZymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)June 12, 2025 | seekingalpha.comBank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)June 12, 2025 | marketbeat.comWellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)June 5, 2025 | marketbeat.comWall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?June 4, 2025 | zacks.comZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2, 2025 | msn.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLCJune 2, 2025 | marketbeat.comVoloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)May 31, 2025 | marketbeat.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comZymeworks’ zanidatamab approved in ChinaMay 30, 2025 | thepharmaletter.comZymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To BudgeMay 30, 2025 | msn.comZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract CancerMay 30, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Zymeworks Inc. (NYSE:ZYME)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT, PHVS, RCUS, and ZYME Company DescriptionsPharvaris NASDAQ:PHVS$17.99 +1.35 (+8.11%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$17.89 -0.10 (-0.58%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Arcus Biosciences NYSE:RCUS$8.66 +0.16 (+1.82%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$8.64 -0.03 (-0.35%) As of 06/20/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Rezolute NASDAQ:RZLT$4.11 +0.04 (+0.98%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.12 +0.00 (+0.12%) As of 06/20/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Zymeworks NYSE:ZYME$12.48 -0.15 (-1.19%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$12.48 -0.01 (-0.04%) As of 06/20/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
